Enhancement of Breast Cancer Therapy by 6-Aminonicotinamide
Abstract
Studies focused on in vivo assessment of enhancing tumor response to radiation (XRT) and adriamycin by pretreatment with 6-aminonicotinamide (6AN) in the hormone sensitive MCF-7. Tumors were inoculated on the flank of nude mice and were studied when they attained a volume of 150 mm3. The dose of 6AN for all experiments was 16 mg/kg which was given 10 hours prior to adriamycin or XRT (5 Gy). The goal of the research conducted under this grant is to investigate the efficacy of 6- aminonicotinamide (6AN) to enhance the effect of radiation and chemotherapy agents that are used in treating breast cancer. This proposal was based on previous work that indicated that 6AN enhanced the effect of radiation in vitro (RIF- 1 tumor cells)(i ,2) and in vivo (3) (breast cancer tumor). The criticism of the latter research was that the studies had not been done in human tumors and therefore we undertook these studies to determine if it was possible to reproduce our previous results in human breast cancer cell/tumors. Our previous in vitro studies from year 1 indicated that 6AN did enhance the effect of radiation and adriamycin, but not paclitaxel (4).
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2000
- Accession Number
- ADA382371
Entities
People
- Jason A Koutcher
Organizations
- Memorial Sloan Kettering Cancer Center